This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study). Physicians treating chronic lymphocytic leukaemia patients with acalabrutinib, where the patients started treatment as part of the acalabrutinib Early Access Programme (EAP), will be invited to recruit patients. Clinical data will be extracted from the patients' clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients who were started on acalabrutinib as part of the UK acalabrutinib EAP.
Treatment-naïve CLL patients who were initiated on acalabrutinib as part of the UK Early Access Programme
Received their first dose of acalabrutinib between 1 April 2020 and 1 April 2021
Patients aged ≥18 years old
Note: patients later found to have small lymphocytic lymphoma (SLL) may also be included in the EAP.
None
AstraZeneca
Lead sponsor
UKCLL Forum
Collaborator